14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -3.594 2 days ( 7.34 % )
Last Price $2.02 -7.34 %
High/ Low $2.02 - $2.21 4.46%
Chg 7 Days -6.05 % $2.15 $2.02
Chg 30 Days -11.40 % $2.28 $2.02
Chg 12 mos -74.04 % $7.78 $2.02
Trend - 3 mos -6.32 % Width: 45.95 %
Trend - 12 mos -66.29 % Width: 1,056.70 %
Pred. range - 3 mos $1.74 - $2.54 -13.84 % - 25.75 %
Pred. range - 12 mos N/A - $0.693 -100.00 % - -65.68 %
Short MA avg 3 mos Sell Apr 23, 2024 - 2 days
Long MA avg 3 mos Sell Apr 11, 2024 - 10 days
Short/Long MA avg 3 mos Sell Apr 16, 2024 - 7 days
Short MA avg 12 mos Sell Apr 11, 2024 - 10 days
Long MA avg 12 mos Sell Apr 11, 2024 - 10 days
Short/Long MA avg 12 mos Sell Sep 27, 2023 - 145 days
Pivot Short Sell Apr 18, 2024 - 5 days
Bollinger Buy Apr 18, 2024 - 5 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Coherus BioSciences

Coherus BioSciences Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ... CHRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT